Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

• Main Authors: Qiao Liu (Author), Zhen Zhou (Author), Xia Luo (Author), Lidan Yi (Author), Liubao Peng (Author), Xiaomin Wan (Author), Chongqing Tan (Author), Xiaohui Zeng (Author)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...